CD274 and neoplasm: Modalities include tumor-targeted monoclonal antibodies; genetically engineered chimeric antigen receptor- (CAR-) or T cell receptor- (TCR-) T cells for adoptive transfer1,2,3; immune checkpoint inhibitors, such as PD-1- and PD-L1-directed antibodies; and T cell engagers (TCEs) to recruit and activate the patients’ T cells and facilitate anti-tumor T cell action.4